Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989980 | 1.00 | PBRM1 (0.53) | PBRM1MAOAMAOBGRM5DRD2 | |
| SCHEMBL4219924 | 0.89 | MAOB (0.62) | PBRM1MAOAMAOBGRM5DRD2 | |
| SCHEMBL29649358 | 0.89 | MAOB (0.62) | PBRM1MAOAMAOBGRM5DRD2 | |
| SCHEMBL7051524 | 0.86 | CASP3 (0.46) | MAOAMAOBDRD2DRD3PNMT | |
| SCHEMBL29741348 | 0.85 | GRM5 (0.62) | MAOAMAOBGRM5DRD2DRD3 | |
| SCHEMBL1031985 | 0.85 | GRM5 (0.62) | MAOAMAOBGRM5DRD2DRD3 | |
| SCHEMBL9377565 | 0.79 | TDP1 (0.58) | MAOAMAOBDRD2DRD3PNMT | |
| SCHEMBL29618340 | 0.78 | DRD2 (0.42) | MAOAMAOBDRD2DRD3PNMT | |
| SCHEMBL8084215 | 0.78 | TDP1 (0.61) | MAOAMAOBDRD2DRD3PNMT | |
| SCHEMBL31125133 | 0.77 | BAZ1A (0.56) | PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591727-A | Organic long-afterglow luminescent material, preparation and application | 中国科学院上海有机化学研究所 | 2022-06-07 | — | — | CN | claimed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| CN-114591727-A | Organic long-afterglow luminescent material, preparation and application | 中国科学院上海有机化学研究所 | 2022-06-07 | — | — | CN | disclosed |
| CN-114127638-A | Negative photosensitive resin composition, cured film, organic EL display, and method for producing cured film | 东丽株式会社 | 2022-03-01 | — | — | CN | disclosed |
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-1910338-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM, LLC (BM) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| US-RE37438-E1 | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. | 2001-11-06 | — | — | US | disclosed |
| US-5866612-A | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0799191-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
| EP-0357742-B1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES | ROUSSEL-UCLAF (FR) | 1993-06-09 | — | — | EP | disclosed |
| US-5180741-A | Insecticides | ROUSSEL UCLAF (FR) | 1993-01-19 | — | — | US | disclosed |
| EP-0357742-A1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES. | ROUSSEL UCLAF (FR) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989008096-A1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES | ROUSSEL-UCLAF (FR) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | PBRM1 4322/4885MAOA 1139/4885MAOB 926/4885 |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | PBRM1 2212/4885MAOA 1265/4885MAOB 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.